ZT 031

Drug Profile

ZT 031

Alternative Names: cPTH (1-31); Cyclic hPTH-(1-31)-NH2 injection; Ostabolin injection; Ostabolin-C injectable; Ostabolin-C injection; Ostabolin-C injection - Azelon Pharmaceuticals; Parathyroid hormone analogue injection - Azelon Pharmaceuticals

Latest Information Update: 05 Aug 2015

Price : $50

At a glance

  • Originator Zelos Therapeutics Inc
  • Developer Azelon Pharmaceuticals
  • Class Osteoporosis therapies; Peptide fragments; Peptide hormones
  • Mechanism of Action Osteogenesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Osteodystrophy; Osteoporosis; Postmenopausal osteoporosis

Most Recent Events

  • 15 Dec 2011 No development reported - Phase-II for Postmenopausal osteoporosis in Canada (SC)
  • 15 Dec 2011 No development reported - Preclinical for Osteoporosis in Canada (Intranasal)
  • 15 Dec 2011 No development reported - Phase-I for Osteodystrophy in Canada (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top